Table II.

Peak day of clinical disease and CDS of mice receiving E3 DCs and Pb DCs with or without LPS exposure

DC Treatment	CDS	Peak (d)
E3	5.2 ± 5.2*	0.4 ± 0.4*
E3 + LPS	7.0 ± 4.3**	0.9 ± 0.6
Pb	23.6 ± 7.7	1.9 ± 0.6
Pb + LPS	21.9 ± 6.4	1.8 ± 0.5

Protection from autoimmunity was maintained, even with inflammatory challenge. Recipients had decreased peak severity, clinical severity, and resolution of clinical signs. Data are representative of three separate experiments, with a total of 10 mice per group. All groups were compared with Pb DC recipients.

^*p < 0.01

^**p < 0.05.